Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New MRI-Guided radiation shows promise for lung cancer treatment

NCT ID NCT05237453

Knowledge-focused Sponsor: University Hospital Heidelberg Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tests whether using real-time MRI to guide radiation therapy is possible for people with advanced non-small cell lung cancer. The goal is to see if this personalized approach can reduce side effects and better control tumors. About 30 adults with stage III lung cancer will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2022

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically-proven non-small cell lung cancer (NSCLC) * Stage III A - C according to the 8th edition of the Union for International Cancer Control (UICC) TNM classification * Indication for definitive thoracic chemoradiotherapy * Age ≥ 18 years * ECOG 0 - 2 * Adequate pulmonary function for chemoradiotherapy confirmed by a current pulmonary function test (≤ 6 weeks from treatment start) * Ability to lie still on the MR-linac table for at least one hour * Ability to hold one's breath for at least 20 seconds * Successful completion of an MR-guided treatment simulation * For women with childbearing potential: adequate contraception * Ability of the patient to understand character and individual consequences of the clinical trial * Written informed consent (must be available before enrolment in the trial) Exclusion Criteria: * Involvement of supraclavicular lymph nodes (supraclavicular N3) * Additional pulmonary lesions (T3 - 4 due to additional lesion in the same or another lobe) * Previous radiotherapy of the lung and mediastinum, if previous and current target volumes overlap * Patients who have not yet recovered from acute toxicities of prior therapies * Contraindications against performing MRI scans (e.g. pacemakers or other implants making MRI impossible) * Pregnant or lactating women * Participation in another competing clinical study or observation period of competing trials * Refusal of the patients to take part in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-small cell lung cancer

Contacts and locations

Locations

  • Ludwig-Maximilian-Universität München

    Münich, Bavaria, 81377, Germany

  • University Hospital of Heidelberg, Radiation Oncology

    Heidelberg, 69120, Germany

  • Universitätsklinikum Tübingen

    Tübingen, Baden-Wurttemberg, 72076, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.